2-(Phenoxazin-10-yl)ethyl methanesulfonate → Ethyl 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-butoxypropanoate
반응식
CS([O:5][CH2:6][CH2:7][N:8]1[C:21]2[CH:20]=[CH:19][CH:18]=[CH:17][C:16]=2[O:15][C:14]2[C:9]1=[CH:10][CH:11]=[CH:12][CH:13]=2)(=O)=O.[CH2:22]([O:26][CH:27]([CH2:33][C:34]1[CH:39]=[CH:38][C:37](O)=[CH:36][CH:35]=1)[C:28]([O:30][CH2:31][CH3:32])=[O:29])[CH2:23][CH2:24][CH3:25]>>[CH:20]1[C:21]2[N:8]([CH2:7][CH2:6][O:5][C:37]3[CH:36]=[CH:35][C:34]([CH2:33][CH:27]([O:26][CH2:22][CH2:23][CH2:24][CH3:25])[C:28]([O:30][CH2:31][CH3:32])=[O:29])=[CH:39][CH:38]=3)[C:9]3[C:14](=[CH:13][CH:12]=[CH:11][CH:10]=3)[O:15][C:16]=2[CH:17]=[CH:18][CH:19]=1참가 물질
3
실험 절차
The title compound (0.25 g, 53%) was prepared as a colorless liquid from 2-(phenoxazin-10-yl)ethyl methanesulfonate (0.3 g, 0.98 mmol) and ethyl 2-butoxy-3-(4-hydroxyphenyl)propanoate (0.26 g, 0.97 mmol) obtained in preparation 6 by an analogous procedure to that described in example 6 (Method B).
후처리
- customobtained in preparation 6 by an analogous procedure to